Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 3,701–3,800 of 15,747
Bruminhent, J., Setthaudom, C., Chaumdee, P., Boongird, S., Kiertiburanakul, S., Malathum, K., Nongnuch, A., Phuphuakrat, A., Jirasiritham, S., Janphram, C., et al. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16867 · Cited by 30
Nejad, M.-M. M., Shobeiri, P., Dehghanbanadaki, H., Tabary, M., Aryannejad, A., Ghadery, A. H., Shabani, M., Moosaie, F., SeyedAlinaghi, S., & Rezaei, N. (2022) · Virology Journal · doi:10.1186/s12985-022-01858-3 · Cited by 30
Anti-PF4 antibodies associated with disease severity in COVID-19
Liu, Q., Miao, H., Li, S., Zhang, P., Gerber, G. F., Follmann, D. A., Ji, H., Zeger, S. L., Chertow, D. S., Quinn, T. C., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2213361119 · Cited by 29
North, C. M., Barczak, A. K., Goldstein, R. H., Healy, B. C., Finkelstein, D. M., Ding, D. D., Kim, A., Boucau, J., Shaw, B. M., Gilbert, R. F., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab643 · Cited by 29
Nucleoside‐modified messenger RNA COVID‐19 vaccine platform
Roncati, L., & Corsi, L. (2021) · Journal of Medical Virology · doi:10.1002/jmv.26924 · Cited by 28
Beta RBD boost broadens antibody-mediated protection against SARS-CoV-2 variants in animal models
Sheward, D. J., Mandolesi, M., Urgard, E., Kim, C., Hanke, L., Vidakovics, L. P., Pankow, A. P., Smith, N. L., Dopico, X. C., McInerney, G. M., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100450 · Cited by 30
Hannauer, F., Black, R., Ray, A. D., Stulz, E., Langley, G. J., & Holman, S. W. (2023) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.9596 · Cited by 35
Nucleic acid delivery and nanoparticle design for COVID vaccines
Andresen, J. L., & Fenton, O. S. (2021) · MRS Bulletin · doi:10.1557/s43577-021-00169-2 · Cited by 37
Jones, D. L., Salazar, A. S., Rodriguez, V. J., Balise, R. R., Starita, C. U., Morgan, K. E., Raccamarich, P. D. C., Montgomerie, E. K., Nogueira, N. F., Ojeda, I. T. B., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab154 · Cited by 30
Thakkar, A., Pradhan, K., Duva, B., Carreño, J. M., Sahu, S., Thiruthuvanathan, V. J., Campbell, S., Gallego, S., Bhagat, T. D., Rivera, J., et al. (2023) · eLife · doi:10.7554/elife.83694 · Cited by 31
“Effective vaccines have been developed and authorized by the FDA to combat this pandemic (Sadoff et al., 2021; Polack et al., 2020).”
Fitzpatrick, D., Young, M. M., Yacisin, K., McElwee, K., Belanger, T., Belanger, K. A., Peng, Y., Lee, D.-Y., Gruber, W. C., Scott, D. A., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.05.002 · Cited by 30
“7 % efficacy in those 65 years old [13].”
BackgroundSelf-citationBai, J., Chiba, A., Murayama, G., Kuga, T., Tamura, N., & Miyake, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.786586 · Cited by 29
“Because mRNA vaccine-mediated protection has been observed before the second dose when the neutralizing antibody is not yet detectable (17), this early CD8 T cell response might play an important role in protection at the early phase after vaccination.”
BackgroundCOVID-19 Vaccines over Three Years after the Outbreak of the COVID-19 Epidemic
Zasada, A. A., Darlińska, A., Wiatrzyk, A., Woźnica, K., Formińska, K., Czajka, U., Główka, M., Lis, K., & Górska, P. (2023) · Viruses · doi:10.3390/v15091786 · Cited by 39
“severe COVID-19 requiring hospitalization and death due to COVID-19 [44].”
BackgroundImmunogenicity of COVID-19 vaccines and their effect on HIV reservoir in older people with HIV
Matveev, V., Mihelic, E. Z., Benko, E., Budylowski, P., Grocott, S., Lee, T., Korosec, C. S., Colwill, K., Stephenson, H., Law, R., et al. (2023) · iScience · doi:10.1016/j.isci.2023.107915 · Cited by 28
“DISCUSSION Recent COVID-19 vaccine trials showed that age had an impact on immunogenicity after one dose of BNT162b2,(24) but this effect diminished with two doses.(25) Phase 3 mRNA-1273 studies showed lower vaccine efficacy in older age groups,(23) and differences between binding and neutralizing Ab responses were al…”
BackgroundRaethke, M., van Hunsel, F. P. A. M., Thurin, N. H., Dureau‐Pournin, C., Mentzer, D., Kovačić, B., Skvrce, N. M., Clercq, E. D., Sabbe, M., Trifirò, G., et al. (2023) · Drug Safety · doi:10.1007/s40264-023-01281-9 · Cited by 28
Seefeld, M. L., Templeton, E. L., Lehtinen, J. M., Sinclair, N., Yadav, D., & Hartwell, B. L. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1419527 · Cited by 35
Felten, R., Dubois, M., Ugarte-Gil, M. F., Chaudier, A., Kawka, L., Bergier, H., Costecalde, C., Pijnenburg, L., Fort, J., Chatelus, E., et al. (2021) · Rheumatology · doi:10.1093/rheumatology/keab432 · Cited by 30
The Role of Cellular Immunity in the Protective Efficacy of the SARS-CoV-2 Vaccines
Sun, Z., Wu, T., Xie, H., Li, Y., Zhang, J., Su, X., & Qi, H. (2022) · Vaccines · doi:10.3390/vaccines10071103 · Cited by 31
Bajrai, L. H., El-Kafrawy, S. A., Hassan, A. M., Tolah, A. M., Alnahas, R. S., Sohrab, S. S., Rehan, M., & Azhar, E. I. (2022) · Scientific Reports · doi:10.1038/s41598-022-26157-3 · Cited by 28
Yamamoto, K. Z., Yasuo, N., & Sekijima, M. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c01087 · Cited by 29
SARS-CoV-2 B.1.1.7 escape from mRNA vaccine-elicited neutralizing antibodies
(2021) · doi:10.21203/rs.3.rs-156101/v1 · Cited by 728
Correlation between COVID-19 vaccination and diabetes mellitus: A systematic review
He, Y., Ouyang, J., Hu, X.-D., Ni, W., Jiang, Z., Bian, N., & Wang, J. (2023) · World Journal of Diabetes · doi:10.4239/wjd.v14.i6.892 · Cited by 34
Coagulopathy and Fibrinolytic Pathophysiology in COVID-19 and SARS-CoV-2 Vaccination
Yamada, S., & Asakura, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063338 · Cited by 34
“The mRNA vaccines work by delivering mRNA (for the formation of spike proteins) protected by lipid nanoparticles to ribosomes in human cells, causing the production of spike proteins [210].”
BackgroundInactivated Vaccines Against SARS-CoV-2: Neutralizing Antibody Titers in Vaccine Recipients
Zhang, H., Jia, Y., Ji, Y., Xu, C., Liu, Y., Yang, R., Kong, X., Shi, Y., Zhu, L., Wang, Z., et al. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.816778 · Cited by 29
Vikström, L., Fjällström, P., Gwon, Y.-D., Sheward, D. J., Byström, J. W., Evander, M., Bladh, O., Widerström, M., Molnár, C., Rasmussen, G., et al. (2023) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2023.100646 · Cited by 32
Nomah, D. K., Reyes‐Urueña, J., Llibre, J. M., Ambrosioni, J., Ganem, F., Miró, J. M., & Casabona, J. (2022) · Current HIV/AIDS Reports · doi:10.1007/s11904-021-00596-5 · Cited by 32
“Regarding mRNA vaccines, in the Moderna and Pfizer trials [55, 56], only 0.”
BackgroundMiguel, C. P. V., Dasgupta-Tsinikas, S., Lamb, G. S., Olarte, L., & Santos, R. P. (2022) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piac099 · Cited by 29
Bačová, B., Kohutová, Z., Zubata, I. K., Gahérová, Ľ., Kučera, P., Heizer, T., Mikesova, M., Karel, T., & Novák, J. (2022) · Clinical and Experimental Medicine · doi:10.1007/s10238-022-00809-0 · Cited by 29
Kang, K., Doroudi, S., Delasay, M., & Wickeham, A. (2022) · Production and Operations Management · doi:10.1111/poms.13675 · Cited by 42
Yanis, A., Haddadin, Z., Spieker, A. J., Waqfi, D., Rankin, D. A., Talj, R., Thomas, L. D., Birdwell, K. A., Ezzell, L. J., Blair, M. A., et al. (2021) · Transplant Infectious Disease · doi:10.1111/tid.13772 · Cited by 33
Bikdeli, B., Jiménez, D., Rodríguez, P. D., Valle, F. G., Porras, J. A., Barba, R., Ay, C., Malý, R., Braester, A., Imbalzano, E., et al. (2022) · Viruses · doi:10.3390/v14020178 · Cited by 27
Nanoparticles‐based double‐stranded RNA delivery as an antiviral agent in shrimp aquaculture
Jonjaroen, V., Charoonnart, P., Jitrakorn, S., Payongsri, P., Surarit, R., Saksmerprome, V., & Niamsiri, N. (2024) · Reviews in Aquaculture · doi:10.1111/raq.12916 · Cited by 33
Intracerebral hemorrhage due to vasculitis following COVID-19 vaccination: a case report
Takeyama, R., Fukuda, K., Kouzaki, Y., et al. (2021) · Acta Neurochirurgica · doi:10.1007/s00701-021-05038-0 · Cited by 27
Einarsdottir, S., Martner, A., Waldenström, J., Nicklasson, M., Ringlander, J., Arabpour, M., Törnell, A., Wiktorin, H. G., Nilsson, S., Bittar, R., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006937 · Cited by 29
Comparing hybrid and regular COVID-19 vaccine-induced immunity against the Omicron epidemic
Huang, L., Lai, F. T. T., Yan, V. K. C., Cheng, F. W. T., Cheung, C. L., Chui, C. S. L., Li, X., Wan, E. Y. F., Wong, C. K. H., Hung, I. F., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00594-7 · Cited by 30
Real world effectiveness of covid-19 vaccines
Hungerford, D., & Cunliffe, N. A. (2021) · BMJ · doi:10.1136/bmj.n2034 · Cited by 25
Zewude, B., Habtegiorgis, T., Hizkeal, A., Wotango, T. D., & Siraw, G. (2021) · Pragmatic and Observational Research · doi:10.2147/por.s344848 · Cited by 27
CNS inflammatory demyelinating events after COVID-19 vaccines: A case series and systematic review
Rinaldi, V., Bellucci, G., Buscarinu, M. C., Reniè, R., Marrone, A., Nasello, M., Zancan, V., Nistri, R., Palumbo, R. A., Salerno, A., et al. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.1018785 · Cited by 29
Targeted nanotherapy for kidney diseases: a comprehensive review
Sabiu, G., Kasinath, V., Jung, S., Li, X., Tsokos, G. C., & Abdi, R. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfac233 · Cited by 33
Impact of Lipid Tail Length on the Organ Selectivity of mRNA-Lipid Nanoparticles
Hashiba, K., Taguchi, M., Sakamoto, S., Otsu, A., Maeda, Y., Suzuki, Y., Ebe, H., Arimichi, O., Harashima, H., & Sato, Y. (2024) · Nano Letters · doi:10.1021/acs.nanolett.4c02566 · Cited by 48
Gene Therapy for Dopamine Dyshomeostasis: From Parkinson's to Primary Neurotransmitter Diseases
Ng, J., Barral, S., Waddington, S. N., & Kurian, M. A. (2023) · Movement Disorders · doi:10.1002/mds.29416 · Cited by 29
“For delivery of RNA therapeutics, non-viral delivery methods are also showing great potential for a broad spectrum of applications; these range from the antisense oligonucleotide therapy, nusinersen for spinal muscular atrophy (SMA) to mRNA based coronavirus disease 2019 (Covid19) vaccinations.(2,3) An important diffe…”
BackgroundVickers, M. A., Sariol, A., Leon, J., Ehlers, A., Locher, A. V., Dubay, K. A., Collins, L. J., Voss, D. R., Odle, A. E., Holida, M. D., et al. (2021) · Transfusion · doi:10.1111/trf.16401 · Cited by 23
Cao, M., Su, X., & Jiang, S. (2021) · Stem Cell Reports · doi:10.1016/j.stemcr.2020.12.010 · Cited by 27
Montgomerie, I., Bird, T. W., Palmer, O. R., Mason, N. C., Pankhurst, T. E., Lawley, B., Hernández, L. C., Harfoot, R., Authier-Hall, A., Anderson, D. E., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106256 · Cited by 28
Sriwastava, S., Shrestha, A. K., Khalid, S. H., Colantonio, M. A., Nwafor, D. C., & Srivastava, S. (2021) · Neurology International · doi:10.3390/neurolint13040061 · Cited by 27
Bhattacharya, A., Ranjan, P., Ghosh, T., et al. (2021) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2021.102238 · Cited by 27
“1% for BNT162b2 and mRNA1273, respectively) in the American population [13].”
Gil-Manso, S., Carbonell, D., López-Fernández, L. A., Miguens, I., Alonso, R., Buño, I., Muñóz, P., Ochando, J., Pion, M., & Correa‐Rocha, R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.726960 · Cited by 26
“In the case of BNT162b2, the primary endpoint was the efficacy of the vaccine against Covid-19 with onset at least 7 days after the second dose (3).”
BackgroundAcute pancreatitis soon after COVID-19 vaccination
Ozaka, S., Kodera, T., Ariki, S., et al. (2022) · Medicine · doi:10.1097/md.0000000000028471 · Cited by 27
Oropharyngeal shedding of herpesviruses before and after BNT162b2 mRNA vaccination against COVID-19
Brosh‐Nissimov, T., Sorek, N., Yeshayahu, M., Zherebovich, I., Elmaliach, M., Cahan, A., Amit, S., & Rotlevi, E. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.08.088 · Cited by 26
“Pfizer/BioNTech’s mRNA COVID-19 vaccine, BNT162b2, has received emergency use authorization by the US FDA on December 11th, 2020 [1], based on a phase III placebo-controlled study of over 40,000 individuals [2].”
Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variantsPreprint
Ikegame, S., Siddiquey, M. N. A., Hung, C.-T., Haas, G. D., Brambilla, L., Oguntuyo, K. Y., Kowdle, S., Vilardo, A. E., Edelstein, A., Perandones, C., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-400230/v1 · Cited by 27
Şendur, S. N., Özmen, F., Oğuz, S. H., İremli, B. G., Malkan, Ü. Y., Gürlek, A., Erbas, T. A., & Ünlütürk, U. (2022) · Thyroid · doi:10.1089/thy.2022.0010 · Cited by 33
Bouazzaoui, A., & Abdellatif, A. A. H. (2024) · Vaccine X · doi:10.1016/j.jvacx.2024.100500 · Cited by 44
“…of mRNA into cells using different methods including Lipid-Based Systems and Polymer-Based Systems, making RNA-based platform the most efficient method for vaccination, and conducting to development of different vaccines such as BNT162b1 from Pfizer [32] and mRNA-1273 from Moderna [30] (Fig.”
BackgroundMethodInfluentialArcucci, V., Stacker, S. A., & Achen, M. G. (2021) · Biomolecules · doi:10.3390/biom11020249 · Cited by 28
Endogenous HClO-Gated Cascade MicroRNA Imaging for Precise Diagnosis of Atherosclerosis In Vivo
Ji, M., Dong, J., Ye, Z., Kang, J., Han, G., Hong, X., Wei, Y., Chen, X., Sun, W. Y., & Liu, D. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c00031 · Cited by 31
Levy, I., Levin, E. G., Olmer, L., Regev‐Yochay, G., Agmon‐Levin, N., Wieder-Finesod, A., Indenbaum, V., Herzog, K. K., Doolman, R., Asraf, K., et al. (2022) · Vaccines · doi:10.3390/vaccines10081220 · Cited by 29
“Systemic adverse events were selected based on the most common reactions that presented in the phase 3 study of the vaccine [1].”
BackgroundBusic, N., Lucijanić, T., Baršić, B., Lukšić, I., Bušić, I., Kurdija, G., Barbić, L., Kunštek, S., Jelić, T., & Lucijanić, M. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27666 · Cited by 25
MalagodaPathiranage, K., Cavac, E., Chen, T.-H., Roy, B., & Martin, C. T. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad027 · Cited by 34
Zamfir, M.-A., Moraru, L., Dobrea, C. M., Scheau, A.-E., Iacob, S. A., Moldovan, C., Scheau, C., Căruntu, C., & Căruntu, A. (2022) · Medicina · doi:10.3390/medicina58070874 · Cited by 28
“The most common side effects were local or systemic minor reactions, such as arm pain at the site of injection, fever, and headache [25].”
BackgroundMagicova, M., Zahrádka, I., Fialova, M., Neskudla, T., Gurka, J., Módos, I., Hojny, M., Raška, P., Smejkal, P., Stříž, I., et al. (2022) · Transplantation · doi:10.1097/tp.0000000000004044 · Cited by 30
Dermatomyositis post vaccine against SARS-COV2
Camargo‐Coronel, A., Jiménez-Balderas, F. J., Quiñones-Moya, H., Hernández-Zavala, M. R., Rodríguez, P. M., Vázquez, J. R. H., Zarco, S. Z., & Castillo, S. D. J. A. (2022) · BMC Rheumatology · doi:10.1186/s41927-022-00250-6 · Cited by 28
“00016% of the vaccinated population), so, in case of proving causal relation the risk of presenting this complication would be very low and wouldn’t compare to the potential benefits of the vaccine [13].”
BackgroundSinger, S. R., Angulo, F. J., Swerdlow, D. L., McLaughlin, J. M., Hazan, I., Ginish, N., Anis, E., Mendelson, E., Mor, O., Zuckerman, N. S., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101190 · Cited by 32
“The results from the present study, supported by data from Qatar [26] and the recent additional RCT analysis of South African participants, [30] demonstrates real-world protection against SARS-CoV-2 infections caused by Beta, and provide reassurance that the BNT162b2 vaccine can be used effectively in settings where B…”
InfluentialCOVID-19 vaccine-induced cellulitis and myositis
Ramalingam, S., Arora, H., Lewis, S., et al. (2021) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.88a.21038 · Cited by 27
Sharun, K., Singh, R. P., & Dhama, K. (2021) · Annals of Medicine and Surgery · doi:10.1016/j.amsu.2021.102264 · Cited by 28
VacSIM: Learning effective strategies for COVID-19 vaccine distribution using reinforcement learning
Awasthi, R., Guliani, K. K., Khan, S. A., Vashishtha, A., Gill, M. S., Bhatt, A., Nagori, A., Gupta, A., Kumaraguru, P., & Sethi, T. (2022) · Intelligence-Based Medicine · doi:10.1016/j.ibmed.2022.100060 · Cited by 43
Acute myocarditis associated with anti-COVID-19 vaccination
Nevet, A. (2021) · Clinical and Experimental Vaccine Research · doi:10.7774/cevr.2021.10.2.196 · Cited by 28
“Novel anti-coronavirus disease 2019 (COVID-19) vaccines were developed and approved recently by regulatory authorities for a wide population, as part of a global effort to cope with the COVID-19 pandemic and its consequences [1].”
BackgroundMay, D., Rubin, B. E., Dalai, S. C., Patel, K. J., Shafiani, S., Elyanow, R., Noakes, M. T., Snyder, T. M., & Robins, H. S. (2021) · medRxiv · doi:10.1101/2021.12.20.21267877 · Cited by 30
da Silva, M. K., Campos, D. M. D. O., Akash, S., Akter, S., Leow, C. Y., Fulco, U. L., & Oliveira, J. I. N. (2023) · Viruses · doi:10.3390/v15102130 · Cited by 30
Klaassen, F., Chitwood, M. H., Cohen, T., Pitzer, V. E., Russi, M., Swartwood, N. A., Salomon, J. A., & Menzies, N. A. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac438 · Cited by 26
Wu, J., Li, J., Liu, J., Wang, H., Zhou, G., Li, J., Wu, D., Chen, X., Feng, Y., Qi, X., et al. (2023) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(23)00199-8 · Cited by 28
Watanabe, K., Watanabe, C., Honma, T., Tian, Y., Kawashima, Y., Kawashita, N., Takagi, T., & Fukuzawa, K. (2021) · The Journal of Physical Chemistry Letters · doi:10.1021/acs.jpclett.1c00663 · Cited by 27
Ko, Y., Lee, J., Kim, Y.-J., Kwon, D., & Jung, E. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18126469 · Cited by 29
“Public Health 2021, 18, 6469. https://doi.org/10.3390/ijerph18126469 https://www.mdpi.com/journal/ijerph 2020, and the first vaccinations began in England [4].”
BackgroundInfluentialAn Acute Exacerbation of Idiopathic Pulmonary Fibrosis After BNT162b2 mRNA COVID-19 Vaccination
Ghincea, A., Ryu, C., & Herzog, E. L. (2022) · CHEST Journal · doi:10.1016/j.chest.2021.07.2160 · Cited by 26
“In one large cohort of vaccinated patients, the most common adverse events included local and benign systemic reactions; SAEs were exceedingly rare.(7) Interestingly, this cohort included 1,478 individuals with chronic lung disease, although rates of SAEs among this group were unavailable.”
BackgroundImpact of scaling up SARS-CoV-2 vaccination on COVID-19 hospitalizations in Spain
Barandalla, I., Alvarez-Domínguez, C., Barreiro, P., de Mendoza, C., Crespo, R. A. G., & Soriano, V. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.09.022 · Cited by 31
Corowa-kun: A messenger app chatbot delivers COVID-19 vaccine information, Japan 2021
Kobayashi, T., Nishina, Y., Tomoi, H., Harada, K., Tanaka, K., Matsumoto, E., Horimukai, K., Ishihara, J., Sasaki, S., Inaba, K., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.06.007 · Cited by 30
Effects of N95 Mask Use on Pulmonary Function in Children
Lubrano, R., Bloise, S., Marcellino, A., Ciolli, C. P., Testa, A., Luca, E. D., Dilillo, A., Mallardo, S., Isoldi, S., Martucci, V., et al. (2021) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2021.05.050 · Cited by 29
Keppler‐Hafkemeyer, A., Greil, C., Wratil, P. R., Shoumariyeh, K., Stern, M., Hafkemeyer, A., Ashok, D., Hollaus, A., Lupoli, G., Priller, A., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00502-x · Cited by 33
COVID-19 Vaccine Failure in a Patient with Multiple Sclerosis on Ocrelizumab
Chilimuri, S. S., Mantri, N., Gongati, S., Zahid, M., & Sun, H. (2021) · Vaccines · doi:10.3390/vaccines9030219 · Cited by 28
Li, M., Wang, Z., Xie, C., & Xia, X. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.04.011 · Cited by 39
Khanna, N., Chatterji, T., Singh, S., & Pandey, S. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104958 · Cited by 31
Lyu, X., Hu, J., Xu, X., Xianyu, Y., & Dong, W. (2021) · BMC Nursing · doi:10.1186/s12912-021-00591-6 · Cited by 35
“To date, the safety and effectiveness of several new coronavirus vaccines have been verified by large-scale clinical trials, such as the BNT162b2 mRNA COVID-19 vaccine [11], mRNA-1273 SARS-CoV-2 vaccine [12], AZD1222 vaccine [13], and CoronaVac vaccine [14].”
BackgroundDutta, T., Baildya, N., Khan, A. A., & Ghosh, N. N. (2021) · Network Modeling Analysis in Health Informatics and Bioinformatics · doi:10.1007/s13721-021-00309-3 · Cited by 27
“2020 saw the development and testing of some COVID-19 vaccines (Fontanet et al. 2021; Baden et al. 2021; Polack et al. 2020).”
BackgroundAn MPXV mRNA-LNP vaccine candidate elicits protective immune responses against monkeypox virus
Tian, Y., Li, M., Yang, Y., Li, C., Peng, Y., Yang, H., Zhao, M., Wu, P., Ruan, S., Huang, Y., et al. (2023) · Chinese Chemical Letters · doi:10.1016/j.cclet.2023.109270 · Cited by 27
Sandoval, C., Guerrero, D., Muñoz, J., Godoy, K., Souza‐Mello, V., & Farías, J. G. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2023.2156861 · Cited by 31
“In addition, the vaccines met both main efficacy endpoints with a greater than 99.99% probability of efficacy [10,45].”
BackgroundInfluentialImmuno-Endocrinology of COVID-19: The Key Role of Sex Hormones
Tramontana, F., Battisti, S., Napoli, N., & Strollo, R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.726696 · Cited by 30
“First reports on COVID-19 vaccine unfortunately were not powered to provide evidence of safety and efficacy by sex (44) although the point estimates of efficacy for subgroups was also high, consistent with that observed in the overall study population (45).”
ResultNasir, N. M., Joyosemito, I. S., Boerman, B., & Ismaniah, I. (2021) · Jurnal Pengabdian kepada Masyarakat UBJ · doi:10.31599/jabdimas.v4i2.662 · Cited by 48
Szebeni, G. J., Gémes, N., Honfi, D., Szabó, E. V., Neuperger, P., Balog, J. Á., Nagy, L. I., Szekanecz, Z., Puskás, L. G., Toldi, G., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.846248 · Cited by 36
“PBMCs were divided into 3 wells for the following samples (1): untreated, (2) S-M-N Peptivator (Miltenyi Biotec, Germany) stimulated, (3) polyclonal activator stimulated”
MethodTriple jeopardy in ageing: COVID-19, co-morbidities and inflamm-ageing
Rea, I. M., & Alexander, H. D. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101494 · Cited by 29
Preclinical evaluation of RQ3013, a broad-spectrum mRNA vaccine against SARS-CoV-2 variants
Tan, S., Zhao, J., Hu, X., Li, Y., Wu, Z., Lu, G., Yu, Z., Du, B., Liu, Y., Li, L., et al. (2023) · 中国科学通报:英文版 · doi:10.1016/j.scib.2023.11.024 · Cited by 26
COVID-19 Vaccine–Associated Takotsubo Cardiomyopathy
Jani, C., Leavitt, J. I., Omari, O. A., Dimaso, A., Pond, K. K., Gannon, S. A., Chandran, A. K., Dennis, C. R., & Colgrove, R. C. (2021) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001379 · Cited by 27
COVID-19 in Solid Organ Transplant Recipients: a Review of the Current Literature
Heldman, M. R., & Kates, O. S. (2021) · Current treatment options in infectious diseases/Current treatment options in infectious disease · doi:10.1007/s40506-021-00249-6 · Cited by 27
“In December 2020, two vaccines containingmessenger RNA encoding the SARS-CoV2 spike protein (mRNA-1273 (Moderna) and BNT162b2 (Pfizer/BioNTech)) were authorized for emergency use in many countries based on promising efficacy data from phase III trials in immunocompetent adults [74, 75].”
MethodSchulze‐Koops, H., Specker, C., & Skapenko, A. (2021) · RMD Open · doi:10.1136/rmdopen-2020-001553 · Cited by 29
Coulaud, P.-J., Ablona, A., Bolduc, N., Fast, D., Bertrand, K., Ward, J. K., Greyson, D. L., Jauffret‐Roustide, M., & Knight, R. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.02.085 · Cited by 29
Impact of SARS‐CoV‐2 infection on vaccine‐induced immune responses over time
Havervall, S., Marking, U. W., Greilert‐Norin, N., Gordon, M., Ng, H., Christ, W., Phillipson, M., Nilsson, P., Hober, S., Blom, K. G., et al. (2022) · Clinical & Translational Immunology · doi:10.1002/cti2.1388 · Cited by 27
“46 47 48 Clinical trials and post marketing effectiveness data have shown that currently used COVID49 19 vaccines protect strongly against hospitalization and death (1-3).”
BackgroundDavenport, B., Catala, A., Weston, S. M., Johnson, R. M., Ardanuy, J., Hammond, H., Dillen, C. A., Frieman, M. B., Catalano, C. E., & Morrison, T. E. (2022) · npj Vaccines · doi:10.1038/s41541-022-00481-1 · Cited by 29
“For instance, currently approved RNA-based vaccines that target 67 the S protein of SARS-CoV-2 are safe and highly effective (25, 26); however, they suffer from 68 multiple-dose requirements and require strict “cold-chain” conditions that limit vaccine distribution 69 and pose constraints on the infrastructure and hea…”
BackgroundGenomics in medicine: A new era in medicine
Pattan, V., Kashyap, R., Bansal, V., Candula, N., Koritala, T., & Surani, S. (2021) · World Journal of Methodology · doi:10.5662/wjm.v11.i5.231 · Cited by 33
A Cost–Benefit Analysis of COVID-19 Vaccination in Catalonia
Seguí, F. L., Català, M., Prats, C., Estrada, O., Oliva, I., Prat, N., Isnard, M., Vallès, R., Vilar, M., Clotet, B., et al. (2021) · Vaccines · doi:10.3390/vaccines10010059 · Cited by 27
“Considering the reported effectiveness of these vaccines in clinical trials [16-19] and in real setting [20], the following ranges of effectiveness have been explored: 60-80% for the incidence of cases, 85-90% in the case of hospitalizations and emergencies and 90-95% in the case of deaths.”
BackgroundKavikondala, S., Haeussler, K., Wang, X., Bausch-Jurken, M. T., Nassim, M., Mishra, N. K., Malmenäs, M., Sharma, P., de Velde, N. V., Green, N., et al. (2024) · Infectious Diseases and Therapy · doi:10.1007/s40121-024-00936-z · Cited by 25
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.